About: Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 1993

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 1993 (uk) im Mai 1993 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en mayu de 1993 (ast) scientific article published on 01 May 1993 (en) գիտական հոդված հրատարակված 1993 թվականի մայիսի 1-ին (hy)
publication date	wds:Q72076251-016AA55A-C38F-4B99-908D-939E0E131EE7
publication date	1993-05-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q72076251-35F33A7B-1CF7-499D-9FAE-54A80E1F8B04
language of work or name	English
author name string	wds:Q72076251-47CAD9D7-A942-4034-9507-0C83589ABBD4 wds:Q72076251-7ABAC815-3BC3-47D7-997F-6892CE08A7A8 wds:Q72076251-844DB4C5-671A-4975-9CC9-8E8C380A0DEF wds:Q72076251-B12A3977-EFC3-4F6F-AF79-071FE37D9E60 wds:Q72076251-B757D5FD-9837-4221-A18B-50995D1C75BE wds:Q72076251-CDDCAA8A-080E-4EF3-9AE1-6A970017E756
author name string	K Akakura N Bruchovsky P S Rennie S L Goldenberg L D Sullivan A R Buckley
rdfs:label	Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen (en) Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen (nl)
skos:prefLabel	Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen (en) Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen (nl)
name	Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen (en) Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen (nl)
title	wds:Q72076251-08514E6C-9D6C-48D0-A9B0-B743FB420642
title	Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen (en)
page(s)	wds:Q72076251-28DEDBEB-0143-49C0-99C9-CD86ECC19136
page(s)	2782-2790
instance of	wds:Q72076251-C99B8C98-2A5F-4A7F-A00F-93CB0946F9EC
instance of	scholarly article
main subject	wds:Q72076251-C2930CD3-E966-4338-8D45-E5B36B4B1495
main subject	apoptotic process
PubMed ID	wds:Q72076251-E0EC87D1-0E73-4E2A-859F-315E4403D62B
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7682149
PubMed ID	7682149
published in	wds:Q72076251-2E4AC2AD-A508-4C9D-8DFC-812EF9E0348F
published in	Cancer
issue	wds:Q72076251-0280CDCA-53AF-482D-BBD8-B8978EBCE58F
volume	wds:Q72076251-63D003AD-D021-4FF5-96D8-4C1E023F8B2F
issue	9
volume	71
DOI	wds:Q72076251-0F3B35F1-0F3C-40B0-BB8E-2A75D84344D6
DOI	http://dx.doi.org/10.1002/1097-0142(19930501)71:9%3C2782::AID-CNCR2820710916%3E3.0.CO;2-Z
DOI	10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72076251
is cites work of	Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer An update on androgen deprivation therapy for prostate cancer Low-dose cyproterone acetate plus mini-dose diethylstilbestrol—A protocol for reversible medical castration Focal therapy for prostate cancer 1996: maximizing outcome Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report Molecular action of androgen in the normal and neoplastic prostate Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Androgen-repressed phenotype in human prostate cancer Intermittent androgen suppression for rising PSA level after radiotherapy Intermittent androgen deprivation--questions remain Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells Hormonal therapy: historical perspective to future directions Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails Loss of androgen receptor transcriptional activity at the G(1)/S transition Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer Intermittent versus continuous androgen deprivation in prostate cancer How is androgen-dependent metastatic prostate cancer best treated? Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer Therapeutic effects of leuprorelin microspheres in prostate cancer Intermittent androgen deprivation therapy: redefining the standard of care? Intermittent androgen deprivation: clinical experience and practical applications Molecular mechanisms of castration-resistant prostate cancer progression Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma Hormone refractory prostate cancer Androgens and prostate cancer: biology, pathology and hormonal therapy Current status of intermittent androgen suppression in the treatment of prostate cancer Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice Intermittent androgen deprivation Intermittent androgen suppression in prostate cancer: the Canadian experience Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma Intermittent androgen suppression in the management of prostate cancer Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance Pharmacotherapeutic management of locally advanced prostate cancer: current status Intermittent versus continuous androgen suppression for prostatic cancer Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models Intermittent androgen suppression for prostate cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 169 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software